DTC

EQS-News: ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION

Retrieved on: 
Wednesday, April 10, 2024
Microsoft Exchange Server, Therapy, DTC, ADC, OTCQB, Generation, Spacecraft, News, Defense, Rope

Bei Tests als therapeutisches Vakzin bei einem Melanom-Modell führte ARM-002TM in Kombination mit dem Immuncheckpoint-Inhibitor Anti-PD1 in 80 % der Fälle zu einer vollständigen Reaktion.

Key Points: 
  • Bei Tests als therapeutisches Vakzin bei einem Melanom-Modell führte ARM-002TM in Kombination mit dem Immuncheckpoint-Inhibitor Anti-PD1 in 80 % der Fälle zu einer vollständigen Reaktion.
  • Darüber hinaus können entwickelte Immunzellen zu einem lang anhaltenden immunologischen Gedächtnis führen, das Patienten vor späteren Krebsrückfällen schützen kann.
  • Defence hat sich dafür entschieden, seinen AccuTOX®-Leitkandidaten zu testen, um einen Krebsimpfstoff der zweiten Generation zu entwickeln, da dieser bei einer intratumoralen Verabreichung in geringeren Dosierungen nachweislich die Antigenpräsentation in Krebszellen verbessert.
  • Der Kern der Defence Therapeutics-Plattform besteht in der ACCUM®-Technologie, die einen präzisen Transport von Impfantigenen oder ADCs in intakter Form zu den Zielzellen ermöglicht.

ANNOUNCEMENT OF INVITATION TO VOLUNTARY TENDER OFFER TO THE HOLDERS OF X5 RETAIL GROUP N.V., GLOBAL DEPOSITARY RECEIPTS – ISIN US98387E2054

Retrieved on: 
Wednesday, April 10, 2024
Offer and acceptance, Date, Form, DTC, Issuer, Security (finance), Cryptocurrency

The date and time by which holders must validly tender Securities in order to be eligible to receive an Acceptance Notice and instruct a settlement.

Key Points: 
  • The date and time by which holders must validly tender Securities in order to be eligible to receive an Acceptance Notice and instruct a settlement.
  • As soon as reasonably possible from receipt of an Acceptance Form, that is confirmed by the Offeror to be valid.
  • Holders that wish to accept the Offer are requested to complete the Form of Acceptance and send this directly to the Offeror via email to [email protected] .
  • Forms of Acceptance received by the 6th of May 2024 will receive a Confirmation Notice.

ANNOUNCEMENT OF INVITATION TO VOLUNTARY TENDER OFFER TO THE HOLDERS OF GLOBALTRANS INVESTMENT PLC GDR's - US37949E2046

Retrieved on: 
Wednesday, April 10, 2024
Offer and acceptance, Date, Form, DTC, Issuer, Settlement date, Security (finance)

The date and time by which holders must validly tender Securities in order to be eligible to receive the relevant Purchase Price on the Settlement Date.

Key Points: 
  • The date and time by which holders must validly tender Securities in order to be eligible to receive the relevant Purchase Price on the Settlement Date.
  • As soon as reasonably possible from receipt of an Acceptance Form, that is confirmed by the Offeror to be valid.
  • Holders that wish to accept the Offer are requested to complete the Form of Acceptance and send this directly to the Offeror via email to [email protected] .
  • Forms of Acceptance received by the 6th of May 2024 will receive a Confirmation Notice.

EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE

Retrieved on: 
Wednesday, April 10, 2024
Antigen presentation, Neoplasm, Microsoft Exchange Server, DTC, Therapy, Vaccination, Melanoma, OTCQB, Antigen, Vaccine

When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.

Key Points: 
  • When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.
  • Compared to current anti-cancer strategies, vaccination can stimulate specific immune responses capable of potentially curing established tumors.
  • In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses.
  • Although the ARMTM vaccine can effectively present antigens to responding T cells, the large amount of antigen preparation required to generate the cellular vaccine might represent challenges in the clinic.

Learn the Latest Insights on Generative AI from Industry Leaders at Transform! @InfoComm 2024

Retrieved on: 
Monday, April 8, 2024
Object Management Group, Synthetic media, Transform, GM, Conference, Organization, Health, Transport, Infocommunications, Digital twin, Standardized approach, DTC, Safety, Generative

“Generative AI is reinventing businesses across industries, especially when combined with digital twins,” said Ron Zahavi, Conference Director.

Key Points: 
  • “Generative AI is reinventing businesses across industries, especially when combined with digital twins,” said Ron Zahavi, Conference Director.
  • @Infocomm offers the opportunity to gain insight and engage with industry leaders at the forefront of this technological advancement,” said Dan Isaacs, GM, and CTO of DTC.
  • Generative AI is a large part of the following sessions on the Transform!
  • @InfoComm.

H World Group Limited Announces Put Right Notification for 3.00% Convertible Senior Notes due 2026

Retrieved on: 
Monday, April 1, 2024
Put, FICC, Exercise, CUSIP, Wilmington Trust, DTC, NOTES, PARTIES, Note, Depository Trust Company, Indenture, Debt-to-GDP ratio, National Association, PUT, Security (finance)

SHANGHAI, April 01, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (Nasdaq: HTHT and HKEx: 1179, the “Company” or “H World”), a key player in the global hotel industry, today announced that it is notifying holders of its 3.00% Convertible Senior Notes due 2026 (CUSIP No.

Key Points: 
  • SHANGHAI, April 01, 2024 (GLOBE NEWSWIRE) -- H World Group Limited (Nasdaq: HTHT and HKEx: 1179, the “Company” or “H World”), a key player in the global hotel industry, today announced that it is notifying holders of its 3.00% Convertible Senior Notes due 2026 (CUSIP No.
  • The Put Right expires at 5:00 p.m., New York City time, on Monday, April 29, 2024.
  • The Put Right entitles each holder of the Notes to require the Company to repurchase all or a portion of such holder’s Notes in principal amounts equal to US$1,000 or integral multiples thereof.
  • On the Repurchase Date, the repurchase price will be paid in cash to the holders who exercise the Put Right.

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth-Quarter and Full-Year Fiscal 2023 Results; Posts 11% Annual Sales Growth; Announces 3% Increase in Quarterly Dividend

Retrieved on: 
Thursday, March 28, 2024
Employment, Growth, EPS, Lilly Pulitzer, Capital expenditure, Acquisition, Life, DTC, GAAP, Inventory, Video game

For the fourth quarter, full-price DTC sales were $265 million in fiscal 2023 compared to $258 million in the prior year fourth quarter.

Key Points: 
  • For the fourth quarter, full-price DTC sales were $265 million in fiscal 2023 compared to $258 million in the prior year fourth quarter.
  • Full-price e-commerce sales of $478 million increased $66 million, or 16% for the year, including a $53 million increase for Johnny Was.
  • Outlet sales of $73 million increased $7 million, or 10% for the year, including a $3 million increase for Johnny Was.
  • Capital expenditures in fiscal 2024 are expected to be approximately $200 million compared to $74 million in fiscal 2023.

STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

Retrieved on: 
Wednesday, March 27, 2024
Growth, Webcast, Tax, International, Bank statement, Dermatology, DTC, Acne, Direct, Annual report, Report, Interest, Safety, SSKN, ID, Marketing, STRATA, Video game

Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.

Key Points: 
  • Global recurring revenues for the fourth quarter of 2023 were $5.6 million, as compared to global recurring revenues of $6.5 million for the fourth quarter of 2022.
  • Equipment revenues were $3.1 million for the fourth quarter of 2023, as compared to $4.1 million for the fourth quarter of 2022.
  • Selling and marketing costs for the fourth quarter of 2023 were $2.8 million, as compared to $3.8 million for the fourth quarter of 2022.
  • Other expenses for the fourth quarter of 2023 were $0.4 million, compared to $0.2 million for the fourth quarter of 2022.

NuCana Announces Plan to Implement ADS Ratio Change

Retrieved on: 
Wednesday, March 27, 2024
Tax, Sale, ADS, DTC, DRS, Depository Trust Company, NCNA, Effective date, Depositary, American depositary receipt, Security (finance)

EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio").

Key Points: 
  • EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio").
  • The change in the ADS Ratio is expected to become effective on or about April 16, 2024 (the "Effective Date").
  • For the Company's ADS holders, the change in the ADS Ratio has the same effect as a one-for-twenty-five reverse ADS split and will have no impact on an ADS holder’s proportional equity interest in the Company.
  • As a result of the change in the ADS Ratio, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the change in the ADS Ratio will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the change in the ADS Ratio will have any effect on the liquidity in the Company’s ADSs.

Solectrac Announces Strategic Reorganization to Further Amplify Electrification Efforts and Enhance Customer Support

Retrieved on: 
Wednesday, March 27, 2024
EV, Environment, TIPS, Plant, DTC, B Corporation (certification), Zoo, Tree, Animal, Renewable energy

Solectrac has been awarded e-tractor vendor status with two prominent national cooperative purchasing agencies: The Interlocal Purchasing System (TIPS) and The Association of Educational Purchasing Agencies (AEPA).

Key Points: 
  • Solectrac has been awarded e-tractor vendor status with two prominent national cooperative purchasing agencies: The Interlocal Purchasing System (TIPS) and The Association of Educational Purchasing Agencies (AEPA).
  • This program perfectly aligns with Solectrac's mission to support the transition to a cleaner, more sustainable future in the agricultural sector.
  • With CORE’s support, Solectrac has already sold more than 60 tractors to date.
  • The pilot will help the North Carolina Zoo reach its goal of reducing greenhouse gas emissions by 30% by 2025.